What Does the Market Think of CVS Health (CVS) Shares?

This afternoon we watched CVS Health drop -1.1% to a price of $66.34 per share. The large-cap Pharmaceutical Retail company is now trading -27.54% below its average target price of $91.56. Analysts have set target prices ranging from $76.0 to $110.0 per share for CVS Health, and have given the stock an average rating of buy.

The stock has a very low short interest at 1.5%, and a short ratio of 2.13. The company's insiders own 0.18% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 79.9% of CVS Health's shares being owned by this investor type.

Institutions Invested in CVS Health

Date Reported Holder Percentage Shares Value
2023-06-30 Vanguard Group Inc 9% 116,676,882 $7,740,927,878
2023-06-30 Blackrock Inc. 7% 93,734,850 $6,218,838,737
2023-06-30 State Street Corporation 4% 55,877,387 $3,707,185,308
2023-06-30 Morgan Stanley 3% 33,253,424 $2,206,198,455
2023-06-30 Capital World Investors 2% 30,490,802 $2,022,912,295
2023-06-30 Geode Capital Management, LLC 2% 23,325,287 $1,547,516,194
2023-06-30 FMR, LLC 2% 21,292,797 $1,412,670,642
2023-06-30 Invesco Ltd. 1% 17,002,487 $1,128,030,020
2023-06-30 Bank of America Corporation 1% 16,551,119 $1,098,084,010
2023-06-30 Dodge & Cox Inc 1% 16,024,422 $1,063,140,297

Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on CVS Health.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.